UNIGE document Scientific Article
previous document  unige:76362  next document
add to browser collection
Title

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

Authors
Huttner, Angela
Eickmann, Markus
show hidden authors show all authors [1 - 22]
Published in The Lancet Infectious Diseases. 2015, vol. 15, no. 10, p. 1156–1166
Abstract Safe and effective vaccines against Ebola could prevent or control outbreaks. The safe use of replication-competent vaccines requires a careful dose-selection process. We report the first safety and immunogenicity results in volunteers receiving 3 × 10(5) plaque-forming units (pfu) of the recombinant vesicular stomatitis virus-based candidate vaccine expressing the Zaire Ebola virus glycoprotein (rVSV-ZEBOV; low-dose vaccinees) compared with 59 volunteers who had received 1 ×10(7) pfu (n=35) or 5 × 10(7) pfu (n=16) of rVSV-ZEBOV (high-dose vaccinees) or placebo (n=8) before a safety-driven study hold.
Identifiers
PMID: 26248510
Full text
Article (Published version) (1.8 MB) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research groups Centre de vaccinologie et d'immunologie néonatale (177)
Groupe Desmeules Jules (pharmacologie/toxicologie) (567)
Groupe Laurent Kaiser (virologie clinique) (668)
Rôle du CD44 (809)
Mécanisme de l'inflammation articulaire (44)
Epidémiologie clinique (115)
Citation
(ISO format)
HUTTNER, Angela et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. In: The Lancet Infectious Diseases, 2015, vol. 15, n° 10, p. 1156–1166. https://archive-ouverte.unige.ch/unige:76362

174 hits

0 download

Update

Deposited on : 2015-10-22

Export document
Format :
Citation style :